First-pass extracted concept

Irbesartan Diabetic Nephropathy Trial

Candidate: concept label1 source documents4 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

IDNT

Evidence Snippets

The discovered sources explicitly refer to the anchor study as IDNT, enabling trial-name normalization.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2001New England Journal of MedicineDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1mechanism independencesupports2001Source 1DOI PubMed

The renoprotective effect of irbesartan was not explained by differences in achieved blood pressure and was independent of blood-pressure reduction.

Claim 2negative resultsupports2001Source 1DOI PubMed

There were no significant differences in death from any cause or in the cardiovascular composite end point among treatment groups.

Claim 3therapeutic effectsupports2001Source 1DOI PubMed

Irbesartan lowered the risk of doubling of serum creatinine compared with placebo and amlodipine.

Claim 4therapeutic effectsupports2001Source 1DOI PubMed

Irbesartan reduced the risk of the primary composite renal end point compared with placebo and amlodipine in hypertensive patients with nephropathy due to type 2 diabetes.